Cargando…
Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro
BACKGROUND: RNA interference technology has shown high therapeutic potential for cancer treatment. However, serum instability, poor tissue permeability and non-specific uptake of short interfering RNA (siRNA) limit its administration in vivo. To overcome these limitations and improve the specificity...
Autores principales: | Hong, Shanshan, Zhang, Xiaoyan, Chen, Jun, Zhou, Jiabing, Zheng, Yufang, Xu, Congjian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843555/ https://www.ncbi.nlm.nih.gov/pubmed/24252539 http://dx.doi.org/10.1186/1757-2215-6-80 |
Ejemplares similares
-
Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy
por: Zhang, Mengyu, et al.
Publicado: (2018) -
Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer
por: Hong, Shan-Shan, et al.
Publicado: (2018) -
Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo
por: Zhang, Ming-Xing, et al.
Publicado: (2018) -
Profile of follicle-stimulating hormone and polymorphism of follicle-stimulating hormone receptor in Madrasin cattle with ovarian hypofunction
por: Utomo, Budi, et al.
Publicado: (2020) -
Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism
por: Zhang, Meng, et al.
Publicado: (2020)